Forbes | Eyedrop Recall Casts Light On Lack Of Testing For U.S. Drugs
In a Forbes article, contributing editor Arthur L. Kellermann, focuses on how generic drugs are a bargain, but not verifying their quality and safety through independent testing puts patients at risk. This risk can be minimized if products are regularly tested, and problems are promptly reported to the FDA and shared with the public. Focusing on quality and price should keep consumer costs low and ensure a safer and more reliable drug supply.
View the full article via Forbes.
